MétaCan
Menu
← Back to cohort
Record W4416776940 · doi:10.1016/j.vaccine.2025.128016

Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study

2025· article· en· W4416776940 on OpenAlexafffundabout
Pierre-Philippe Piché-Renaud, C. Arianne Buchan, Catherine Burton, Hugo Chapdelaine, Aamir Jeewa, Shaun K. Morris, Jeffrey M. Pernica, Anne Pham‐Huy, Manish Sadarangani, Marina I. Salvadori, Sneha Suresh, Tahir S Kafil, Juthaporn Cowan, Karina A. Top

Bibliographic record

VenueVaccine · 2025
Typearticle
Languageen
FieldMedicine
TopicSARS-CoV-2 and COVID-19 Research
Canadian institutionsPublic Health Agency of CanadaInstitute for Clinical Evaluative SciencesUniversity of OttawaMcMaster UniversityMcMaster Children's HospitalHospital for Sick ChildrenStollery Children's HospitalChildren's Hospital of Eastern OntarioBC Children's HospitalCentre Hospitalier de l’Université de MontréalOttawa HospitalUniversity of TorontoSickKids Foundation
FundersInstitute of Infection and ImmunityCanadian Institutes of Health ResearchMichael Smith Health Research BCBC Children's HospitalPublic Health Agency of CanadaBC Children’s Hospital FoundationUniversity of Ottawa
KeywordsMyopericarditisMyocarditisAdverse effectImmunizationVaccinationChest pain

Abstract

fetched live from OpenAlex

INTRODUCTION: Myocarditis and pericarditis are well-described rare adverse events following immunization (AEFI) associated with COVID-19 mRNA vaccines. Safety data on revaccination among people with previous cardiac AEFIs are lacking. This study assessed outcomes of COVID-19 revaccination among participants assessed for cardiac AEFIs. METHODS: The Special Immunization Clinic Network database, containing data from consented participants across twelve sites, was analyzed. Cases were classified using the Brighton Collaboration Case Definitions (BCCDs) for mutually exclusive diagnoses of myocarditis, myopericarditis or pericarditis. Subjects with cardiac symptoms not meeting the BCCD and with no alternative diagnosis were categorized as chest pain/other cardiac diagnosis. Revaccination recommendations were based on physician judgment, informed by national guidelines. Participants were followed up to 42 days after revaccination to capture AEFI recurrence. RESULTS: Between January 1, 2021 and February 23, 2023, 114 participants were enrolled, including 46 with myocarditis (40.4 %), 26 (22.8 %) with myopericarditis, 11 (9.6 %) with pericarditis, and 31 (27.1 %) with chest pain/other cardiac diagnosis. Twenty-seven of 71 participants (38.0 %) who required further COVID-19 vaccine doses were recommended for revaccination. Sixteen participants were revaccinated: two with myocarditis, two with myopericarditis, two with pericarditis and 10 with chest pain/other cardiac diagnosis. Four adults had recurrent symptoms of the AEFI: 2/10 with previous chest pain/other cardiac diagnosis, one participant with previous pericarditis and multiple comorbid conditions, and one participant with previous myopericarditis who required hospitalization. CONCLUSIONS: COVID-19 mRNA revaccination may be considered for individuals with chest pain not meeting criteria for myocarditis but caution is warranted in adults with prior confirmed myopericarditis post-COVID-19 mRNA vaccination.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.983
Threshold uncertainty score0.123

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.004
Science and technology studies0.0030.001
Scholarly communication0.0010.001
Open science0.0020.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.396
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueVaccine→Same topicSARS-CoV-2 and COVID-19 Research→French-language works237,207→